Health Technology Assessments by the National Institute for Health and Clinical Excellence: A Qualitative Study

Portada
Springer Science & Business Media, 2007 M11 30 - 245 páginas

First in a new series on economic issues in the context of health care policy, Health Technology Assessments by the National Institute for Health and Clinical Excellence examines Britain’s highly acclaimed approach to cost-effectiveness analysis (CEA), and its international potential.

The National Institute for Health and Clinical Excellence (NICE) has been regarded as a role model for the implementation of CEA, and is being closely watched by health care policy makers throughout Europe, and in the United States. This volume dissects the robustness of the agency’s technology appraisal processes as NICE evaluates innovative methods for diagnosis and intervention. Given the unique features of attention-deficit/hyperactivity disorder (ADHD)—starting with it being diagnosed mainly in children and adolescents, its high comorbidity with other psychiatric conditions, and its considerable economic impact—the disorder is a perfect focal point for discussion.

 

Contenido

9780387719962_1_OnlinePDFpdf
2
9780387719962_2_OnlinePDFpdf
20
9780387719962_4_OnlinePDFpdf
37
9780387719962_5_OnlinePDFpdf
46
9780387719962_6_OnlinePDFpdf
118
9780387719962_7_OnlinePDFpdf
171
9780387719962_BookBackmatter_OnlinePDFpdf
188
9780387719962_BookBackmatter_OnlinePDF_Refpdf
206
9780387719962_BookBackmatter_OnlinePDF_Indexpdf
241
Derechos de autor

Otras ediciones - Ver todas

Términos y frases comunes

Pasajes populares

Página 211 - SD, et al. (1997). Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: Effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 589-596.
Página 223 - FR, et al. (2001). Atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled, dose-response study.
Página 233 - A. (1982). How do hyperactive children feel about taking stimulants and will they tell the doctor?

Acerca del autor (2007)

Michael Schlander is founder and chairman of the independent Institute for Innovation & Valuation in Health Care (InnoValHC), a non-profit, non-partisan scientific organization dedicated to research related to the utilization, effectiveness, efficiency, and quality of health care, with particular emphasis on novel approaches of service provision. He teaches health economics and innovation management at the University of Duisburg-Essen (Faculty of Medicine, since 2005) and at the University of Applied Economic Sciences Ludwigshafen, Germany (since 2002). Prior to his university appointment, he spent fifteen years in senior positions with international pharmaceutical companies in Germany, Belgium, and the United States, and six years in experimental brain research and clinical neurology at German universities.

Información bibliográfica